Search
BMY.US: No Accelerated pathway does not imply registrational failure
Bristol's announcement that it is not pursuing an accelerated FDA approval pathway for Yervoy and Opdivo in first line lung cancer was predictable
top of page
bottom of page
Bristol's announcement that it is not pursuing an accelerated FDA approval pathway for Yervoy and Opdivo in first line lung cancer was predictable
Comments